Last reviewed · How we verify
NCT07138716
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
NA trial testing 68Ga-DOTA-CCK-FS PET/CT in Medullary Thyroid Carcinoma in 30 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Luo Yaping |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 10 May 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-DOTA-CCK-FS PET/CT
Conditions studied
- Medullary Thyroid Carcinoma — all drugs for Medullary Thyroid Carcinoma →
Sponsor
Luo Yaping
Who can join
Eligibility, any sex, with Medullary Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof. Luo Yaping (PUMCH Nuclear Medicine) and Prof. Liu Zhibo (Peking University, radiochemistry expert), the trial will enroll 30-40 patients to compare 68Ga-DOTA-CCK-FS imaging with standard PET/CT (e.g., 18F-FDG or 68Ga-DOTATATE). The novel tracer shows higher tumor uptake and retention in preclinical studies, potentially improving diagnosis and treatment guidance for aggressive, CCK-2R-expressing cancers. The study leverages PUMCH's Class IV Radioactive Drug License for advanced radiopharmaceutical development. Risks are minimal (diagnostic radiation dose only), and participants receive free imaging assessments. Results aim to refine precision diagnostics for MTC and related tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.
Stauff E, Karimi H, Kecskemethy HH, Shaffer TH, et al · · 2025 · PMID 41282032 · DOI 10.3389/fmed.2025.1658588
Verify or expand the search:
- PubMed search for NCT07138716
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Medullary Thyroid Carcinoma
Currently open trials in the same condition.
- NCT07383246 — CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC · Phase 3 · recruiting
Other Luo Yaping trials
Trials by the same sponsor.
- NCT06973798 — The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Functio · NA · not yet recruiting
- NCT07138729 — Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis · NA · recruiting
- NCT07104058 — A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07138716 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Luo Yaping
- Last refreshed: 24 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07138716.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing